Proteasome inhibition reduces plasma cell and antibody secretion, but not angiotensin II-induced hypertension
IntroductionDepletion of mature B cells affords protection against experimental hypertension. However, whether B cell-mediated hypertension is dependent on differentiation into antibody-secreting cells (ASCs) remains unclear. Using the proteasome inhibitor, bortezomib, the present study tested the e...
Main Authors: | Hericka Bruna Figueiredo Galvao, Quynh Nhu Dinh, Jordyn M. Thomas, Flavia Wassef, Henry Diep, Alex Bobik, Christopher G. Sobey, Grant R. Drummond, Antony Vinh |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1184982/full |
Similar Items
-
Association of constipation with increased risk of hypertension and cardiovascular events in elderly Australian patients
by: Courtney P. Judkins, et al.
Published: (2023-07-01) -
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024-03-01) -
The role of proteasomes in tumorigenesis
by: Xiangyi Zhou, et al.
Published: (2024-07-01) -
The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
by: Michael A. Harris, et al.
Published: (2020-05-01) -
Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01)